H.C. Wainwright analyst Edward White initiated coverage of Inhibikase Therapeutics with a Buy rating and $5 price target. Inhibikase is a clinical-stage pharmaceutical company with the aim to develop treatments for neurodegenerative diseases, the analyst tells investors in a research note. The firm says IkT-148009 takes a different approach to Parkinson’s disease.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on IKT:
- Inhibikase Therapeutics Reports Full Year 2022 Financial Results and Highlights Recent Period Activity
- Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
- Inhibikase Therapeutics provides interim update from study of IkT-001Pro
- Inhibikase Therapeutics up 19% after FDA lifts full clinical hold
- Inhibikase Therapeutics: FDA lifts full clinical hold on IkT-148009
